Neurotech International Ltd. (AU:NTI)

ASX:NTI

NTI

Neurotech International

RESEARCH TOOLSreports

Want to see AU:NTI full AI Analyst Report?

Neurotech International (NTI) Price & Analysis

11 Followers

NTI Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.03

Previous CloseN/A

Volume11.09K

Average Volume (3M)768.84K

Market Cap

AU$15.81M

Enterprise ValueAU$5.80M

Total Cash (Recent Filing)AU$6.34M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding1,317,741,700

10 Day Avg. Volume770,041

30 Day Avg. Volume768,844

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.26

Price to Sales (P/S)6.36

P/FCF Ratio-1.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Minimal DebtHaving zero reported debt materially reduces solvency and interest-service risk for a clinical-stage biotech. This preserves financial flexibility to pursue R&D, partnerships or equity raises without debt covenants, improving resilience while development milestones are pursued.

Focused R&D Business ModelA narrow, clinical-stage focus on cannabinoid therapies concentrates management expertise, R&D spending and regulatory strategy. This specialization can create durable competitive advantages via IP, regulatory approvals and partnerships if clinical milestones are met, aligning capital to high-value endpoints.

Revenue Rebound Indicates Commercial ActivityA clear revenue rebound from near-zero suggests early commercial traction or increased product/clinical service activity. While small in absolute terms, sustainable top-line growth reduces reliance on financing, helps scale fixed costs and is a necessary precursor to durable margin improvement.

Bears Say

Accelerating Negative Free Cash FlowWorsening free cash flow signals rising cash burn as operations ramp. For a pre-commercial clinical firm, persistent negative FCF forces reliance on external capital, increases dilution risk and constrains the ability to fund trials and regulatory work without material financing events.

Deep And Persistent Operating LossesVery negative EBIT and net margins indicate the current business scale cannot cover operating costs. Without substantial revenue growth or structural cost reduction, losses are likely to persist, undermining profitability prospects and making business success contingent on high-risk clinical outcomes.

Shrinking Equity Base / Funding PressureA material fall in equity reflects accumulated losses and possible dilution, weakening the balance sheet buffer. Combined with negative cash flow, the reduced equity base increases reliance on external financing and raises execution risk for multi-stage clinical programs.

Neurotech International News

Neurotech Director Options Expire Without Exercise

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International has reported a change in...

3d ago

NTI

Neurotech Options Lapse, Trimming Potential Future Dilution

An update from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has notified the market that...

3d ago

NTI

Maybank Securities Exits Substantial Holder Position in Neurotech International

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has disclosed that Maybank Securities...

8d ago

NTI

Neurotech Showcases Paediatric Neurology Drug NTI164 at Hong Kong Investment Summit

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International will present its lead cannabinoid-based...

19d ago

NTI

Neurotech Director Mark Davies Increases Indirect Shareholding

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has disclosed a change in director Mark...

1M ago

NTI

Neurotech clears secondary trading for new share issue

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has issued new fully paid...

1M ago

NTI

Neurotech International Seeks ASX Quotation for 21.4 Million New Shares

Neurotech International ( ($AU:NTI) ) just unveiled an announcement. Neurotech International Limited has applied for quotation on the...

1M ago

NTI

Neurotech to Highlight Paediatric Neurology Pipeline at NWR Virtual Healthcare Conference

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International, a clinical-stage biopharmaceutical company specialising in paediatric...

1M ago

NTI

Neurotech Flags Risks and Uncertainties in Neurodevelopmental Drug Strategy

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has outlined its current corporate...

1M ago

NTI

Neurotech Investors Back Capital Raisings and Director Participation at General Meeting

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has reported the results of its 12...

2M ago

NTI

NTI FAQ

What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.

What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$15.81M.

When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 124 days.

How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,317,741,700 shares outstanding.

What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Neutral

Fundamentals

Return on Equity

-87.19%

Trailing 12-Months

Asset Growth

5.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurotech International Ltd.

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.